Madrigal Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MDGL research report →
About the company
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH).
- CEO
- William J. Sibold
- IPO
- 2007
- Employees
- 528
- HQ
- West Conshohocken, PA, US
Price Chart
- Market Cap
- $12.18B
- P/E
- -41.26
- P/S
- 10.75
- P/B
- 28.21
- EV/EBITDA
- -43.73
- Div Yield
- 0.00%
- Gross Margin
- 93.07%
- Op Margin
- -27.68%
- Net Margin
- -27.32%
- ROE
- -50.15%
- ROIC
- -35.20%
- Revenue
- $958.40M · 432.05%
- Net Income
- $-288,284,000 · 38.12%
- EPS
- $-12.85 · 41.32%
- Op Income
- $-300,097,000
- FCF YoY
- 58.42%
- 52W High
- $615.00
- 52W Low
- $284.02
- 50D MA
- $508.68
- 200D MA
- $497.09
- Beta
- -1.06
- Avg Volume
- 326.35K
Get TickerSpark's AI analysis on MDGL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 17, 26 | Taub Rebecca | other | 454 |
| Jun 17, 26 | Taub Rebecca | other | 766 |
| Jun 17, 26 | Levy Richard S | other | 454 |
| Jun 17, 26 | Levy Richard S | other | 766 |
| Jun 17, 26 | FOUSE JACQUALYN A | other | 454 |
| Jun 17, 26 | FOUSE JACQUALYN A | other | 766 |
| Jun 17, 26 | Daly James M | other | 454 |
| Jun 17, 26 | Daly James M | other | 766 |
| Jun 17, 26 | Brennan Daniel J. | other | 404 |
| Jun 17, 26 | Brennan Daniel J. | other | 681 |
Our MDGL coverage
Recent articles, reports, and earnings notes.
Want a deeper read on MDGL?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.